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LETTERS TO JCP
Pulmonary mucinous cystic
tumour of borderline
malignancy: a rare variant of
adenocarcinoma
Pulmonary mucinous cystic tumours of low or
borderline malignant potential (PMTBMs)
are extremely rare. These tumours have a very
good prognosis and as such should be
distinguished from usual type pulmonary
adenocarcinoma. Here, we describe a case of
PMTBM that arose in a 48 year old male non-
smoker. He presented to respiratory physi-
cians with right lower lobe pneumonia that
failed to improve with antibiotic treatment.
Sputum cytology revealed adenocarcinoma
cells but at bronchoscopy no endobronchial
tumour was seen. A right lower lobectomy
was performed. Macroscopically, the lobec-
tomy specimen contained an ill defined cystic
lesion containing mucin. This measured
15 × 8 × 10 cm.
The tumour comprised tall columnar mucin
secreting cells with minimal cytological atypia
(fig 1) and no mitoses. The tumour cells lined
spaces containing mucin and scattered single
cells. No solid tumour areas were identified.
Mucus dissection through the peribronchial
spaces in a manner reminiscent of pseu-
domyxoma peritonei was seen (fig 2).
Tumour cells expressed cytokeratin 20
(CK20) strongly and CK7 weakly (fig 3). CK7
staining was also seen in pneumocytes and
respiratory epithelium. There was focal ex-
pression of epithelial membrane antigen by
tumour cells; however, there was no expres-
sion of carcinoembryonic antigen or chromo-
granin A. There was no evidence of metastatic
carcinoma in the lymph nodes identified. The
surrounding lung parenchyma showed bron-
chitis and organising pneumonia.
PMTBMs are very rare, with only 38 cases
having been reported to our knowledge.1–7 The
presentation varies from an incidental finding
in an asymptomatic patient to persistent
cough, chest pain, dyspnoea, pneumothorax,
and pneumonia, which fails to resolve with
antibiotics.1 At the time of surgery, the
tumours are usually staged as T2 owing to
their size. Adequate sampling of the specimen
is as important as in ovarian tumours because
cellularity is variable throughout these tu-
mours. PMTBMs are histologically similar to
appendiceal and ovarian mucinous tumours
of borderline malignancy, with the micro-
scopic features as described above. Lymph
node involvement is not a feature.
Normal pulmonary parenchyma does not
express CK20; however, pneumocytes and
respiratory epithelium express CK7. Non-
mucinous bronchioloalveolar carcinoma, mu-
cinous bronchioloalveolar carcinoma, and
conventional pulmonary adenocarcinomas
with a bronchioloalveolar pattern at the
periphery show constant but variable expres-
sion of CK7. These last two tumours also
express CK20.8 In our case, the tumour cells
stained strongly with CK20 and weakly with
CK7.
The most difficult microscopic distinctions
are between PMTBM and cystic bronchioloal-
veolar carcinoma and PMTBM and bronchi-
oloalveolar carcinoma arising from a congeni-
tal cyst. Cystic bronchioloalveolar carcinoma
tends to be more cellular than PMTBM, with
cysts often formed secondary to necrosis,9 and
previously normal x rays may exclude bron-
chioloalveolar carcinoma arising from con-
genital cysts. The exclusion of metastases
from the ovary, appendix, and pancreas
requires comprehensive clinical and radiologi-
cal examination because immunohistochem-
istry is unlikely to be helpful. Other differen-
tial diagnoses include non-neoplastic
mucinous cysts, mucinous cystadenoma of
the bronchus, and mucoceles. These lack the
cytological atypia and paucicellular mucus
dissection of peribronchial spaces seen in
PMTBM.
The term borderline implies a tumour of
low malignant potential, rather than a tumour
of no malignant potential, and this is reflected
in the five year survival figures. Graeme-Cook
et al stated that inherent in the diagnosis of
borderline malignant tumour is an expected
five year survival rate of between 75% and
95%.1 The optimal curative treatment for these
tumours is surgery. In view of the excellent
prognosis of PMTBM, these tumours should
be distinguished from conventional pulmo-
nary adenocarcinomas.
H Monaghan, DM Salter
Department of Pathology, Edinburgh University
Medical School, Teviot Place, Edinburgh EH8 9AG,
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Figure 1 Tall columnar mucin secreting
cells with minimal cytological atypia
(haematoxylin and eosin; original
magnification, ×20).
Figure 2 Mucus dissection through the
peribronchial spaces in a manner reminiscent
of pseudomyxoma peritonei (haematoxylin
and eosin; original magnification, ×4).
Figure 3 Tumour cells stained with
antibodies to cytokeratin 20 (CK20) and
CK7 (original magnification, ×10).
CK20 CK7
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Renal oncocytoma with a novel
chromosomal rearrangement,
der(13)t(13;16)(p11;p11),
associated with a renal cell
carcinoma
Oncocytoma is a benign epithelial tumour
that makes up approximately 5–7% of pri-
mary renal neoplasms.1 This tumour can be
bilateral or multifocal and in 10% of cases
there is an association between oncocytoma
and renal cell carcinoma.2 We report the case
of a renal oncocytoma associated with a
necrotic and cystic clear cell carcinoma. A
cytogenetic study of the oncocytoma showed
a new chromosomal rearrangement, namely:
der(13)t(13;16)(p11;p11).
A 75 year old man with an unremarkable
medical history presented with abdominal
pain. Echotomography and an abdominal
computed tomography scan showed two solid
tumours in the right kidney. The first tumour
measured 4.5 cm, was located at the lower
pole of the kidney, and appeared to be
necrotic. The second tumour measured 3 cm,
was homogeneous, and was located in the
periphery of the first tumour. A radical right
nephrectomy was performed.
Gross examination showed two tumours at
the lower pole of the kidney. The first tumour
measured 4.5 cm in its largest diameter. It was
partially cystic and largely necrotic. The
second tumour measured 3 cm. It was solid,
homogeneous, and had a brown to mahogany
colour.
Fresh samples of the tumours were im-
mersed in RPMI for short term culturing.
Failure of the culture was observed for the
large necrotic tumour.
The kidney was immersed in 10% buffered
formalin and routinely processed for paraffin
wax embedding; 4 µm sections were cut and
stained with haematoxylin and eosin and saf-
fron. Histochemical study was performed
using the Hale’s colloidal iron staining (Mow-
ry’s method). Sections from paraffin wax
embedded material were stained with a panel
of antibodies using the streptavidin–biotin–
peroxidase complex technique. The antibodies
used were: pancytokeratin (KL1; Immu-
notech, Marseille, France; 1/150 dilution),
anticytokeratin 7 (Dako, Trappes, France;
1/150 dilution), and antivimentin (Dako;
1/100 dilution).
Cytogenetic analysis was performed on
RHG (R bands obtained by heating and
Giemsa) banding metaphases according to
conventional procedures. Multitarget fluores-
cence in situ hybridisation (M-FISH) tech-
niques were also performed on metaphase
spreads to confirm the cytogenetic abnormal-
ity (Spectra Vysion DNA probe; Vysis,
Downers Grove, USA). The M-FISH result was
confirmed by specific chromosome painting
(Oncor, Qbiogene, Illkinch, France). Specific
telomeric probes (Cytocell, Banbury, UK) of
this chromosome defined which arm was
implicated in the translocation.
On microscopic examination, the first
tumour was largely necrotic and a few sheets
of tumour cells were identified (fig 1). The
tumour cell cytoplasm was large and clear.
The nuclei were round to oval, with a central
nucleolus (Furhman’s nuclear grade II). No
granular cells were found. Immunohisto-
chemical staining of the clear cell tumour
showed positivity with antibodies to pancy-
tokeratin and vimentin, and negativity for
cytokeratin 7.
The second lesion was entirely composed of
nests and tubulocystic structures of large
eosinophilic and granular cells (fig 2). The
nuclei were round or oval with minimal
atypia. A small nucleolus was frequently seen.
No necrosis or areas of clear cells were
observed. The mitotic count was low (one
mitotic figure/20 high power fields).
Hale’s colloidal iron staining was negative.
Oncocytic cells were positive with antibody to
pancytokeratin but staining for vimentin and
cytokeratin 7 was negative.
Karyotyping of oncocytic cells showed a lost
of the Y chromosome and a translocation of a
piece of an autosome on chromosome 13 (fig
3). M-FISH analyses identified the addition to
chromosome 13 to be a partial chromosome
16 translocation (fig 4) (confirmed by 16 spe-
cific whole chromosome painting). After FISH
studies, the result of this karyotype was: 45, X,
add(13)(p11.ish der(13))t(13;16)(p11;p11)
(wcp16+),inv(16qh). This unbalanced 16
translocation induces a complete 16p trisomy.
Renal oncocytoma is a benign epithelial
neoplasm which is now well defined.1 Histo-
logical criteria are: tumour composed of an
exclusive or predominant component of
granular eosinophilic cells arranged in nests
or tubulocystic structures. Areas of clear cells,
pronounced necrosis, and papillary forma-
tions are lacking by definition.1 Dechet et al
reported bilaterality and multicentricity in 5%
of cases and an association with renal cell car-
cinoma in 10%.2 The main differential diagno-
sis for oncocytoma is chromophobe renal cell
carcinoma. Cytological features (wrinkled
nuclei, perinuclear halos, binucleation), histo-
chemical staining (positivity of Hale’s iron
staining), and ultrastructural study (intracy-
toplasmic microvesicules) are helpful for the
diagnosis of chromophobe cell carcinoma.3
Cytogenetic studies showed different profiles.
In chromophobe renal cell carcinoma, the
most common karyotypic abnormalities are:
loss of chromosomes 1, 2, 6, 10, 13, 17, and
21.4 Cytogenetic studies of oncocytomas have
reported several clonal abnormalities but no
recurrent aberration. The most common are
loss of chromosome Y or 1.5 Translocations
affecting chromosome 11 have also been
described, namely: t(9;11)(p23;q23)6 and
t(5;11)(q35;13).7 8 Other rare chromosome
rearrangements have been reported, such as:
t(1;12)(p36;q13),9 loss of chromosome 14,10
and gain of chromosome 12.5 In a recent
study, Tickoo et al reported 14 cases of diffuse
renal involvement by numerous oncocytic
nodules with features of oncocytoma and
chromophobe renal cell carcinoma.11 These
authors proposed the term renal oncocytosis.
They also suggested that these lesions may
constitute a morphological spectrum of
oncocytic tumours. Dijkhuizen et al proposed
that renal oncocytoma characterised by loss of
chromosomes 1 and Y may progress to
chromophobe renal cell carcinoma with
subsequent losses of chromosomes 2, 6, 10,
13, 17, and 21.12 Here, we describe an
additional new chromosomal rearrangement,
der(13)t(13;16)(p11;p11), in a morphologi-
cally typical oncocytoma.
Figure 1 Necrotic and haemorrhagic
tumour with sheets of large clear cells.
Figure 2 Typical oncocytoma composed of
large granular cells arranged in tubulocystic
structures.
Figure 3 Complete karyotype of one metaphase cell showing: 45, X, add(13)(p11).
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BOOK REVIEWS
Practical Review of
Neuropathology.
Gregory N, Fuller J, Goodman C. 2001, Lip-
pincott Williams & Wilkins, $69.95. ISBN 0
7817 2778 2
This book achieves the authors’ stated objec-
tive of being a succinct overview of contempo-
rary neuropathology. In 343 pages and 17
chapters they have produced a practical book
which is a mine of accessible information.
With three short chapters on cell control,
neurochemistry, and neurogenetics, and two
longer chapters describing the cells of the
nervous system and neuroanatomy, they
introduce the basic scientific concepts of the
subject. The next 10 chapters focus on
diseases of the central nervous system but
also include a chapter on neuromuscular dis-
orders. A section on disorders of peripheral
myelin is found in the chapter on demyelinat-
ing diseases. The book ends with a chapter on
the “Ten most common mistakes in surgical
neuropathology” and a “Lexicon of neuropa-
thology” where definitions, comments on the
uses of stains, and examples of redundant
terminology are found. Each chapter is well
organised and most start by indicating the
perspective of the topic and a list of objectives.
As “confessed and unrepentant lumpers” the
authors provide many bold diagrams and text
boxes giving useful frameworks for address-
ing the often incompletely understood prob-
lems of pathogenesis. The numerous photo-
graphs are all monochrome, and some,
lacking in detail and contrast, are not helpful.
However, this is a relatively minor problem.
This book does exactly what it sets out to do
and, with only six references, is that refresh-
ing rarity, the authors’ view of the subject. It
can be confidently recommended to all inter-
ested in neuropathology, especially trainees,
and to those in general pathology.
J E McLaughlin
Brain Drug Targeting: The
Future of Brain Drug
Development.
Pardridge W M. Cambridge University Press,
2001, £65.00. ISBN 0 521 80077 3
This very timely book describes the state of
the art techniques to target drugs to the brain.
For almost 30 years, the author has been an
inspiring advocate for this field, and is the
author of close to 300 papers in international
peer reviewed journals on this subject.
Neuro(patho)logists consider the blood–
brain barrier as an irreducible fortress. How-
ever, it houses active transport mechanisms
for large pharmacologically engineered mol-
ecules that can also be protected from being
cleared from the blood and peripheral degra-
dation. All the essential and state of the art
science and technology to target drugs to the
brain has been incorporated into this book
and placed in the context of the philosophy of
the author. This has the advantage that it is in
a single context, but at the same time it is
limited to the view of only one person.
Nevertheless, this approach is very important
to provide a fast and fundamental insight into
the various aspects of drug targeting to the
brain.
This book is a comprehensive overview on
the various possibilities of targeting drugs to
the brain, including invasive brain drug deliv-
ery, lipid mediated and carrier mediated
transport of small molecules, receptor medi-
ated transcytosis of peptides, vector discovery
for brain targeting, linker strategies for multi-
drug formulations, protein neurotherapeutics
and peptide radiopharmaceuticals, antisense
neurotherapeutics and imaging gene expres-
sion, gene therapy of the brain, and the
future: blood–brain barrier genomics.
Pardridge has provided us with a book that
will become a standard on drug targeting to
the brain and adds to future hope on curative
instead of palliative treatment of central
nervous system diseases. The book is a must
for everybody who works in the field of brain
drug delivery in academia as well as in the
pharmaceutical industry. Finally, the book is
well referenced with up to date references and
includes a convenient subject index.
W Kamphorst, A G de Boer, P J Gaillard
Figure 4 Multitarget fluorescence in situ hybridisation study showing p16 trisomy by
unbalanced 16 translocation (arrow).
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